Quarterly report [Sections 13 or 15(d)]

Segment Information

v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information

Note 10 - Segment Information

 

The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO, as Chief Operating Decision Maker, assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table is a summary of segment information for three and six months ended June 30, 2026 and 2025 (amounts in thousands):

 

    June 30, 2026     June 30, 2025     June 30, 2026     June 30, 2025  
    For the three months ended     For the six months ended  
    June 30, 2026     June 30, 2025     June 30, 2026     June 30, 2025  
Net revenues                                
Diagnostic services   $ -     $ -     $ -     $ -  
Consumer products     1,011       1,247       2,180       2,678  
Consolidated net revenue     1,011       1,247       2,180       2,678  
Cost of revenue                                
Diagnostic services     -       112       -       344  
Consumer products     785       401       1,659       1,074  
Consolidated cost of revenue     785       513       1,659       1,418  
Depreciation and amortization expense                                
Diagnostic services     -       205       -       539  
Consumer products     623       805       1,245       1,612  
Total Depreciation and amortization expense     623       1,010       1,245       2,151  
Operating and other expenses             -               -  
Diagnostic services     -       1,560       -       1,728  
Consumer products     760       211       1,271       1,272  
Unallocated corporate     1,882       1,646       4,845       4,480  
Total operating and other expenses     2,642       3,417       6,116       7,480  
Income (loss) from operations, before income taxes                                
Diagnostic services     -       (1,877 )     -       (2,611 )
Consumer products     (1,157 )     (170 )     (1,995 )     (1,280 )
Unallocated corporate     (1,882 )     (1,646 )     (4,845 )     (4,480 )
Total loss from operations, before income taxes     (3,039 )     (3,693 )     (6,840 )     (8,371 )
Income tax expense     (12 )     (779 )     (1,386 )     (779 )
Total loss from operations, after income taxes     (3,051 )     (4,472 )     (8,226 )     (9,150 )
Net loss from continuing operations   $ (3,051 )   $ (4,472 )   $ (8,226 )   $ (9,150 )

 

The following table is a summary of segment information as of June 30, 2026 and December 31, 2025 (amounts in thousands):

 

    June 30,     December 31,  
    2026     2025  
ASSETS                
Consumer products   $ 10,309     $ 11,614  
Unallocated corporate     47,100       48,257  
Total assets   $ 57,409     $ 59,871